ANSELL LIMITED (ANN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ANN

ANN - ANSELL LIMITED

FNArena Sector : Commercial Services & Supplies
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.14
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Ansell is an Australian manufacturer of protective industrial equipment and household and medical gloves. It is the remnant of Pacific Dunlop, once a mighty conglomerate that listed in 1985. The name was changed to Ansell in 2002.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$35.73

20 Feb
2025

-0.290

OPEN

$35.88

-0.81%

HIGH

$35.95

364,638

LOW

$35.52

TARGET
$37.216 4.2% upside
OTHER COMPANIES IN THE SAME SECTOR
AIM . ASB . CUP . DGL . KPG . QHL . RDX . SRV .
FNARENA'S MARKET CONSENSUS FORECASTS
ANN: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) 185.3 xxx
DPS (cps) 79.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 19.3 xxx
Dividend Yield 2.2% xxx
Div Pay Ratio(%) 42.6% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.34%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.96

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 26/08 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx90.7
DPS All xxxxxxxxxxxxxxx57.5
Sales/Revenue xxxxxxxxxxxxxxx2,471.1 M
Book Value Per Share xxxxxxxxxxxxxxx1,944.1
Net Operating Cash Flow xxxxxxxxxxxxxxx388.4 M
Net Profit Margin xxxxxxxxxxxxxxx4.72 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx4.45 %
Return on Invested Capital xxxxxxxxxxxxxxx3.35 %
Return on Assets xxxxxxxxxxxxxxx2.70 %
Return on Equity xxxxxxxxxxxxxxx4.45 %
Return on Total Capital xxxxxxxxxxxxxxx8.15 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx211.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx116 M
Long Term Debt xxxxxxxxxxxxxxx1,167 M
Total Debt xxxxxxxxxxxxxxx1,284 M
Goodwill - Gross xxxxxxxxxxxxxxx1,471 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx1,366 M
Price To Book Value xxxxxxxxxxxxxxx1.37

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx95.8 M
Capex % of Sales xxxxxxxxxxxxxxx3.88 %
Cost of Goods Sold xxxxxxxxxxxxxxx1,524 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx649 M
Research & Development xxxxxxxxxxxxxxx25 M
Investments - Total xxxxxxxxxxxxxxx17 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.2

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

11/02/2025

1

Outperform

$40.30

12.79%

Ansell reported 1H25 earnings before interest and tax, which came in better than consensus estimates due to solid growth in both industrial and healthcare, Macquarie notes.

The company also announced better-than-expected revenues, as industrial benefited from growth in mechanical and chemical, offset by slightly increased freight rates. Healthcare saw support from cost savings and fulfilling delayed surgical orders, the analyst states.

Management's revised EPS guidance of US118-US128c implies growth of 12% to 21% compared to prior guidance. Macquarie raises EPS forecasts by 4% for FY25/FY26 following the upgrade in guidance.

Outperform rating unchanged. Target price moves up to $40.30 from $32.

FORECAST
Macquarie forecasts a full year FY25 dividend of 84.28 cents and EPS of 186.26 cents.
Macquarie forecasts a full year FY26 dividend of 93.13 cents and EPS of 210.69 cents.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

ANN STOCK CHART

FNArena News on ANN

1
Rudi’s View: More Beats In Early Feb Results

Feb 19 2025 - Rudi's View
2
FNArena Corporate Results Monitor – 11-02-2025

Feb 11 2025 - Australia
3
Rudi’s View: AGL Energy, Bega Cheese, BRG, Harvey Norman, Imdex & Superloop

Feb 06 2025 - Rudi's View
4
Rudi’s View: Cochlear, Guzman y Gomez, SiteMinder, Wesfarmers & Xero

Jan 30 2025 - Rudi's View
5
Rudi’s View: A Rally With No Earnings Support

Nov 14 2024 - Rudi's View

Latest Commercial Services & Supplies News

1
Pro Medicus’ Valuation Predicament

Feb 19 2025 - Australia
2
Amcor Confident In Berry On Top

Feb 07 2025 - Australia
3
DeepSeek Fuels AI Technology Advances

Feb 06 2025 - Feature Stories
4
DeepSeek & More AI Excitement For 2025

Jan 28 2025 - Feature Stories
5
Xero: The Pause That Refreshes

Jan 23 2025 - Technicals
6
Looking For Durable, Needle-Moving Growth In AI

Jan 13 2025 - International
7
In Brief: Dicker Data, Light & Wonder, Codan

Dec 20 2024 - Weekly Reports
8
Pro Medicus, A Global Software Super Star

Dec 19 2024 - Australia
9
Alliance Aviation Cleared For Dividend Takeoff

Dec 16 2024 - Small Caps
10
The 2024 Gen.Ai Xmas Special, Incl 2025 Outlook

Dec 12 2024 - Australia